Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24633511 | 0.86 | CARM1 (0.35) | SIGMAR1GBA1HRH3CARM1PRMT6 | |
| SCHEMBL21421593 | 0.81 | GBA1 (0.35) | SIGMAR1GBA1CARM1PRMT6 | |
| SCHEMBL22018257 | 0.81 | GNAO1 (0.44) | SIGMAR1GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL24530643 | 0.81 | GNAO1 (0.44) | SIGMAR1GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL25467832 | 0.81 | GNAO1 (0.44) | SIGMAR1GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL22794642 | 0.80 | NPC1 (0.41) | SIGMAR1GNAO1GNAI3GNAI1BCHE | |
| SCHEMBL24372870 | 0.79 | GNAO1 (0.42) | SIGMAR1GNAO1GNAI3GNAI1GBA1 | |
| SCHEMBL19602184 | 0.79 | SIGMAR1 (0.57) | SIGMAR1GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL24684487 | 0.78 | GNAI3 (0.34) | GNAO1GNAI3GNAI1BCHE | |
| SCHEMBL1810789 | 0.78 | HRH3 (0.46) | GNAO1GNAI3GNAI1GBA1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | SIGMAR1 4839/4885GNAO1 1163/4885GNAI3 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.